Background
The prompt resolution of acute inflammation triggered by infectious agents, trauma or chemical stimulus plays an essential role in avoiding chronicity and unwanted tissue damage that could result from an unrestrained response to the original harmful stimulus [
1]. Lipoxins [
2], resolvins [
3,
4] and protectins [
5] are families of endogenously produced, lipid-derived substances that act in the resolution phase of acute inflammatory processes [
6]. A number of recent studies have characterised the mechanisms involved in the synthesis and action of these substances in different inflammatory conditions, providing evidence for their essential role in tissue protection and demonstrating their potential use as therapeutic tools in several diseases [
7‐
10].
Resolvin D2 (RvD2), one of the members of the resolvin family, is produced from the ω3-polyunsaturated fatty acid, docosahexaenoic acid (DHA), as a result of a series of reactions catalysed by lipoxygenases [
3]. The anti-inflammatory and pro-resolution effects of RvD2 are mediated, at least in part, by the pertussis-sensitive G-protein-coupled receptor (GPCR), GPR18, by a signalling mechanism yet to be fully elucidated [
10,
11]. Although most studies have explored the role of resolvins in acute inflammatory conditions, a recent study has provided evidence that both RvD2 and resolvin D1 (RvD1) can modulate the chronic inflammatory process that takes place in the adipose tissue of obese subjects [
12]. In addition, treatment with 17-hydroxydocosahexaenoic acid (17-HDHA), a precursor of RvD2, reduced inflammation and corrected systemic insulin resistance in obese diabetic rodents [
13].
Currently, obesity is one of the most prevalent diseases in the world (
http://www.who.int/mediacentre/factsheets/fs311/en/). It is the main risk factor for type 2 diabetes mellitus (T2D) and is also an important predisposing condition for hypertension, atherosclerosis and some types of cancer [
14]. Saturated fatty acids present in the diet induce an inflammatory response in the hypothalamus, leading to a dysfunctional regulation of caloric intake and energy expenditure [
15‐
19], which plays an important role in the genesis and perpetuation of obesity [
20,
21]. In fact, a number of pharmacological and genetic approaches used to dampen obesity-linked hypothalamic inflammation result in the reversal of the obese phenotype in animal models [
16‐
18,
20,
22]. Recent studies have also shown that increased content of ω3 fatty acids in the diet or direct hypothalamic injection of ω3 fatty acids can reduce obesity-linked hypothalamic inflammation, increase POMC neuron-specific neurogenesis and attenuate the obese phenotype [
23,
24].
Because ω3 fatty acids are precursors of RvD2, we evaluated the activity of this system in the hypothalamus of obese rodents. Here, we demonstrate that consumption of a diet rich in saturated fatty acids reduces the amount of RvD2 in the hypothalamus, while dietary supplementation or direct hypothalamic injection of ω3 fatty acids stimulates its synthesis. Administration of exogenous RvD2 reduces diet-induced hypothalamic inflammation and rescues from the obese phenotype. Thus, direct or indirect methods leading to the increase of RvD2 in the hypothalamus are potentially useful approaches to attenuate hypothalamic inflammation and dysfunction in obesity.
Methods
Chemicals and reagents
All of the reagents for SDS-polyacrylamide gel electrophoresis and immunoblotting were from Bio-Rad (Richmond, CA, USA). HEPES, phenylmethylsulfonyl fluoride, aprotinin, dithiothreitol, Triton X-100, Tween 20, glycerol and BSA (fraction V) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). The antibodies against GPR18 (sc79503), NPY (sc133080) and Iba1 (sc28530) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The reagents for chemiluminescence protein labelling in immunoblots were purchased from Amersham (Aylesbury, UK). FITC-conjugated anti-rabbit (sc2012), FITC-conjugated anti-goat (sc2024), Cy3-conjugated goat anti-mouse (ab6946), Cy3-conjugated donkey anti-goat (ab6949), rhodamine-conjugated anti-rabbit (sc2091) and rhodamine-conjugated anti-goat (sc2094) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The lipid mediator resolvin D2 (sc-351847A) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Reagents for the real-time PCR analysis were from Invitrogen (Carlsbad, CA, USA) and Applied Biosystems (Foster City, CA, USA). TaqMan primers for PLA2 (Mm00448161_m1), 15-LOX (Mm00507789_m1), 5-LOX (Mm01182747_m1), GPR18 (Mm01224541_s1), TNFα (Mm00443258_m1), IL1β (Mm00434228_m1), IL6 (Mm00446190_m1), IL10 (Mm01288386_m1), PGC1α (Mm00447183_m1), UCP1 (Mm01244861_m1) and glyceraldehyde-3-phosphate dehydrogenase (GAPD) (#4352339E) were obtained from Applied Biosystems.
Experimental animals
Male Swiss mice originally imported from Jackson Laboratory and currently bred at the University of Campinas Breeding Center were used in the study. The investigation was conducted in accordance with the principles and procedures described by the National Institutes of Health Guidelines for the Care and Use of Experimental Animals and was previously approved by the University of Campinas Ethical Committee (ID 2011/2341-1). The animals were maintained at 21 ± 3 °C, on a 12-h artificial light/dark cycle and housed in individual cages. By 5 weeks old, the mice were assigned in three groups, with the same body weight mean: standard rodent chow diet (CT), high-fat diet (HF; 60% of energy value from fat, Table
1) and high-fat diet supplemented with omega 3 (HFS; HF supplemented with 20% omega 3, Table
1) by the time specified in the protocol.
Table 1
Composition of the experimental diets
Starch | 427.5 | 115.5 | 115.5 |
Casein | 200 | 200 | 200 |
Dextrin | 132 | 132 | 132 |
Saccharose | 100 | 100 | 100 |
Soy oil | 40 | 40 | 40 |
Lard | 0 | 312 | 104 |
Flaxseed oil | 0 | 0 | 208 |
Dietary fiber | 50 | 50 | 50 |
Minerals | 35 | 35 | 35 |
Vitamins | 10 | 10 | 10 |
Cysteine | 3 | 3 | 3 |
Choline | 2.5 | 2.5 | 2.5 |
kcal/1000 g | 3798 | 5358 | 5358 |
Experimental protocols
For evaluation and characterisation of biosynthetic pathways of RvD2, generated enzymatically from DHA, mice were fed for 16 weeks on either the chow diet or the HF. By the end of this period, the hypothalamus was removed and RNA extracts were employed in the real-time PCR analysis. In another set of experiments, mice were assigned to the HF or chow diet for 16 weeks and another group of mice was assigned to the HF for 8 weeks following 8 weeks on a HF supplemented with 20% omega 3 (HFS). Food intake and body mass were measured during this period. At the 15th week, the animals were subjected to the intraperitoneal glucose tolerance test. Subsequently, the hypothalamus was removed and employed in the MALDI-MSI analysis (as described below) and real-time PCR analysis for the identification and characterisation of RvD2 in this experimental model. In order to determine the impact of direct intracerebroventricular (icv) injection of DHA on the RvD2 system in the hypothalamus, mice were fed a HF for 4 weeks and were subsequently stereotaxically instrumented in a Stoelting stereotaxic apparatus to receive a cannula placed in the lateral hypothalamic ventricle, using the following stereotaxic coordinates: anteroposterior 0.34 mm, lateral 1.0 mm and dorsoventral 2.2 mm. The correct position of the cannula was tested 5 days after surgery by evaluation of the thirst response elicited by intracerebroventricular angiotensin II (10
6 M). After 1 week, icv-cannulated mice were treated once a day for 4 days with 2 μL of saline or 2 μL of DHA (5, 10 or 20 ng). In another experiment, mice were fed a HF for 8 weeks and were subsequently stereotaxically instrumented, as previously described in this section. After 1 week, the icv-cannulated mice were treated once a day for 11 days with 2 μL of saline or 2 μL of RvD2 (3 or 50 ng). The doses of RvD2 were defined based on a previous study [
9]. Food intake and body mass were measured during the treatment period. On the seventh and tenth days of treatment, the animals were subjected to an intracerebroventricular leptin tolerance test and intraperitoneal glucose tolerance test, respectively. In each group, some mice were randomly selected for indirect calorimetry and spontaneous physical activity measurements. At the end of the experiment, the hypothalamus and brown adipose tissue were collected for real-time PCR analysis. Outlines of the different protocols are depicted in the figures that show the respective experiments.
ipGTT and icvLTT
The intraperitoneal glucose tolerance test (ipGTT) and intracerebroventricular leptin tolerance test (icvLTT) were performed on food-deprived (6 h) non-anaesthetised mice. Blood glucose levels were measured using an OptiumTM mini (Abbott Diabetes Care, Alameda, CA, USA) handheld glucometer with appropriate test strips. For ipGTT, a solution of 20% glucose (2.0 g/kg body weight) was administered into the peritoneal cavity. Blood samples were collected from the tail vein at 30, 60, 90 and 120 min for determination of glucose concentrations. The area under the curve (AUC) was calculated using these values. For icvLTT, food intake was measured 2, 4, 6 and 12 h following icv injection of leptin (10−6 M). These values were used for determining leptin sensitivity.
RNA extraction and quantitative real-time PCR
Total RNA was extracted using a commercially available acid-phenol reagent Trizol (Invitrogen Corp.). RNA concentration, purity and integrity were confirmed spectrophotometrically using a Nanodrop (ND-1000; Nanodrop Technologies, Wilmington, DE). The first-strand cDNA was synthesised using SuperScript III reverse transcriptase and random hexamer primers, as described in the manufacturer’s protocol (Invitrogen Corp.) The quantitative PCR was run to determine the expression of TNFα, IL1β, IL6, IL10, PLA2, 15-LOX, 5-LOX and GPR18 in the hypothalamus of mice and to determine the expression of PGC1α and UCP1 in the brown adipose tissue (BAT) of mice using primers supplied with commercially available assays from Applied Biosystems. The endogenous gene was GAPD (glyceraldehyde-3-phosphate dehydrogenase (Applied Biosystems)). A real-time PCR analysis of gene expression was carried out in an ABI Prism 7500 sequence detection system (Applied Biosystems). The optimal concentration of complementary DNA and primers and the maximum efficiency of amplification were obtained through a 5-point, two-fold dilution curve analysis for each gene. Amplification was performed in a 20-μL final volume containing 40–50 ng of reverse-transcribed RNA according to the manufacturer’s recommendations using the TaqMan PCR master mix. Real-time data were analysed using the Sequence Detector System 1.7 (Applied Biosystems). Results were expressed as the relative transcript amount, as previously optimised [
25].
Immunofluorescence staining
For the histological analysis, hypothalamic tissue samples were frozen sectioned and processed routinely for immunofluorescence staining. Coronal sections of the hypothalamus (5 μm) were double-labelled with anti-GPR18 antibodies and specific primary antibodies against markers related to the different cell types, including NPY, POMC and Iba1. Thereafter, the sections were incubated with specific FITC or rhodamine-conjugated IgG secondary antibodies. Immunofluorescence imaging was performed to evaluate the distribution of GPR18 in the mouse’s hypothalamus.
MALDI-MSI analyses
Obtained brain tissue sections were set on MALDI-appropriate stainless steel plates (GMS-Thermo, CA, USA) and then coated with a 10 mg/mL (50% methanol to acetonitrile) solution of alpha-cyano-4-hydroxycinnamic acid (CHCA) matrix (Sigma Aldrich, PA, USA). For an even distribution, a customised system with a commercial airbrush was utilised to spray the matrix. The MALDI-LTQ-XL instrument (Thermo Fisher, San Jose, CA, USA) with a tissue imaging feature was utilised in the mass spectrometry data acquisition. Operating conditions were set as follows: 4 μJ laser power, 50 μm raster step size, standardised sample size of 600 × 600 μm focused on the coronal sections of the hypothalamus, three laser shots per step and 30 eV for the helium collision-induced dissociation in fragmentation reactions (MS/MS). A survey scan was performed in the mass-to-charge ratio (m/z) range of 50 to 500. Samples were analysed in the negative ion mode. Compound structures were proposed using MS/MS data supported by software calculations with Mass Frontier (v. 6.0, Thermo Scientific, CA, USA), as well as previous data from the literature [
25]. Imaging data were run in replicates for all described animal conditions (chow, HF and HDFω3) and were processed using ImageQuest software (Thermo Scientific, San Jose, CA, USA). Relative quantification was performed using ImageJ (National Institutes of Health, USA–Open Source) on images in grey scale. Since the analysed areas were the same size (in pixel numbers) for all the replicates, ImageJ was able to assign a non-dimensional value for each sample image. This result is based on the intensity of each pixel and can be compared among all samples to determine the relative levels of the desired molecule.
Indirect calorimetry and spontaneous physical activity
Oxygen consumption/carbon dioxide production and spontaneous physical activity were measured in the fed animals through a computer-controlled, open-circuit calorimeter system (LE405 gas analyser; Panlab-Harvard Apparatus). Mice were singly housed in clear respiratory chambers and room air was passed through chambers at a flow rate of ten times the body weight of each animal. The air-flow within each chamber was monitored using a sensor (Air Supply and Switching; Panlab-Harvard Apparatus). Gas sensors were calibrated prior to the onset of the experiments using primary gas standards containing known concentrations of O
2, CO
2 and N
2 (liquid air). The analyses were performed over a 24-h period. Outdoor air reference values were sampled after every four measurements. Sample air was sequentially passed through O
2 and CO
2 sensors for the determination of O
2 and CO
2 content, from which the measures of oxygen consumption (VO
2) and carbon dioxide production (VCO
2) were estimated. VO
2 and VCO
2 were calculated by Metabolism version 2.2 software based on the Withers equation and are expressed in millilitres per hour per gram. The respiratory quotient was calculated as VCO
2/VO
2. Energy expenditure was estimated as VO
2/body mass (grams) [
26].
Statistical analysis
All results are reported as mean ± SEM. Differences between the treatment groups were evaluated using an unpaired Student t test or a one-way analysis of variance (ANOVA). When the ANOVA indicated significance, a Tukey-Kramer post hoc test was performed (GraphPad Software, San Diego, CA). p < 0.05 was accepted as being statistically significant.
Discussion
In experimental obesity, the consumption of dietary fats leads to the rapid activation of an inflammatory response in the hypothalamus [
20]. Over time, neurons of the medium-basal hypothalamus involved in the control of food intake and energy expenditure are affected by inflammation and become dysfunctional [
15‐
19]. The anomalous activity of such neurons is characterised, at least in part, by their reduced responsiveness to the adipostatic hormones, leptin and insulin [
18,
31,
32]. In addition, upon prolonged exposure to dietary fats, more dramatic outcomes may occur, such as defects in mitochondrial function [
33,
34], anomalous regulation of autophagy [
35,
36] and the ubiquitin/proteasome system [
21] and, eventually, increased neuronal apoptosis [
15].
Several approaches employing genetic and pharmacological tools to dampen hypothalamic inflammation were successful in reducing adiposity and improving the metabolic phenotypes associated with obesity [
19,
37]. More recently, reduction of diet-induced hypothalamic inflammation and improvement of the obese phenotype were obtained by the use of DHA, either in the diet or directly injected into the hypothalamus [
23]. Since DHA is the substrate for RvD2 synthesis, we decided to evaluate if the hypothalamus is equipped for producing this resolvin, and if so, how would it be regulated in diet-induced obesity.
Initially, using immunofluorescence, we showed that GPR18, the receptor for RvD2, is expressed in the hypothalamus, particularly in POMC and NPY neurons. We could not detect any labelling for GPR18 in the microglia. No previous study has evaluated the expression and distribution of GPR18 in the brain. However, at least one study has used RvD2 to treat chronic pain by injecting the substance into the spine, which suggests that sensory neurons are responsive to this resolvin and may express GPR18 [
38].
Next, we evaluated the hypothalamic expression of enzymes involved in the conversion of DHA to RvD2. Both in lean and obese animals, we detected the presence of all components of the RvD2 synthetic pathway and its receptor. Interestingly, upon high-fat feeding, there was a modulation of expression of all elements of the synthetic pathway and the receptor. PLA2 and 15-LOX were initially inhibited during the first days after beginning the diet and then underwent an increase at late stage obesity. Conversely, 5-LOX was initially stimulated and then normalised. We also measured the amount of RvD2, which was reduced at late stage obesity. A study has shown that exogenous 17-HpDHA reduces inflammation and attenuates insulin resistance in an animal model of obesity [
13]. This could suggest that, in our model, the increased PLA2 and 15-LOX, accompanied by baseline levels of 5-LOX, would intuitively result in the accumulation of endogenous 17-HpDHA. However, rather than activating an anti-inflammatory response, we see an increase of pro-inflammatory markers. This is most possibly due to the fact that both RvD2 and its receptor GPR18 are reduced.
There is very limited information about the production and function of RvD2 in the brain. In a study aimed at developing methods for the detection and measurement of resolvins, the presence of RvD2 was detected in the brain of mice subjected to a stroke, suggesting that it could play a role in attenuation of the ischemic lesion [
29]. Another study evaluated the post-mortem brain of patients with Alzheimer’s disease (AD) [
39]. Interestingly, there was a direct correlation between the cerebrospinal fluid levels of RvD2 and the cognitive scores of the patients. The authors suggested that a defect in the production of resolvins in the brain could be connected to the evolution of AD. Similarly, an experimental study has demonstrated that ageing rats treated with DHA present improved memory, which was accompanied by increased brain levels of RvD2 [
40].
Besides its role as an endogenous substance produced to control the magnitude and duration of inflammation, much attention has been devoted to resolvins because of their potential use as exogenously delivered therapeutic agents [
6]. Some studies have employed DHA or other substrates to induce the synthesis of endogenous RvD2 [
13,
40], whereas others have used RvD2 directly [
38]. Here, we first evaluated the impact of dietary substitution of saturated by unsaturated fats on the activity of the RvD2 system in the hypothalamus; next, we treated mice with DHA-injected icv in the hypothalamus. Last, we treated mice with RvD2 icv in the hypothalamus. All three approaches were very consistent to improve the obesity-associated metabolic phenotype of mice. In addition, both DHA and exogenous RvD2 were capable of inducing the hypothalamic expression of two cytokines with anti-inflammatory activity in the brain, IL10 and IL6. It is worthwhile to mention that, in the case of direct injection of RvD2 in the hypothalamus, the lower dose, 3.0 ng, provided better results than 50 ng. Although we did not explore this difference in detail, in other context, a large dose of resolvin resulted in a less robust anti-inflammatory action, suggesting the existence of a dose-dependent desensitizing effect for this class of substances [
41].
It has been shown that at least some of the beneficial effects of physical activity in the control of food intake and body adiposity are due to the increased expression of IL10 and IL6 in the hypothalamus [
42]. In fact, IL10 can attenuate not only mild inflammatory activity in the hypothalamus, as the one associated with obesity [
42], but also more severe inflammatory activity, such as the one induced by LPS [
43]. Likewise, icv injection of exogenous IL6 can reduce food intake and body mass [
44], whereas endogenous IL6 can mediate some of the beneficial effects of GLP1, reducing food intake and body mass [
45]. Thus, at least part of the effects of RvD2 in the hypothalamus may be mediated by the increased expression of IL6 and IL10.
An important aspect of the beneficial effects of RvD2 in the hypothalamus is its capacity to improve glucose tolerance in obese mice. Although this effect could be due to body mass reduction, recent studies have shown that the simple attenuation of diet-induced hypothalamic inflammation can, through neural connections, reduce hepatic glucose output [
46] while increasing insulin production [
47]. Testing this hypothesis was not a goal of the present study; however, as glucose tolerance improved with short-term use of RvD2 (11 days) and even in the presence of a mild body mass reduction, we propose that at least part of the effect could be due to neural mechanisms. This is further supported by the fact that, upon RvD2 treatment, there were increased expressions of UCP1 and PGC1α in the BAT, which is known to be mediated by sympathetic inputs [
48].
Acknowledgements
We thank Erika Roman, Joseane Morari, Gerson Ferraz and Marcio Cruz from the University of Campinas for their technical assistance. Fundação de Amparo a Pesquisa do Estado de São Paulo and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico provided the funding for this study. The Laboratory of Cell Signaling belongs to the Obesity and Comorbidities Research Center.